biologic

Vaxchora

Cholera Vaccine, Live, Oral

Loss of exclusivityDecember 2032projected — 12-year biologic exclusivity estimate
CompanyBavarian Nordic A/S

Drug detail

Brand nameVaxchora
Active ingredientCholera Vaccine, Live, Oral
Strength100ML
Dosage formSuspension
RouteOral
ModalityBiologic
FDA approvalDecember 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vaxchora patent cliff — loss of exclusivity December 2032 | CliffBio